Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two ⁸⁹Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens

Table 1

Effect of mAb dose on tumor-to-blood and tumor-to-organ uptake ratios of ⁸⁹Zr-amatuximab (111 kBq/2, 10 or 60 µg) or ⁸⁹Zr-B3 (74 kBq/2, 15 or 60 µg) in nude mice with A431/H9 tumor. All values are reported as mean ± standard deviation ().

mAb	Time	Injection dose	Tumor/blood	Tumor/liver	Tumor/kidney	Tumor/spleen	Tumor/muscle
Amatuximab	24 h	2 µg
Amatuximab	24 h	10 µg
Amatuximab	24 h	60 µg
B3	24 h	2 µg
B3	24 h	15 µg
B3	24 h	60 µg